Thiogenesis Announces Non-Brokered Private Placement

• Thiogenesis Therapeutics Corp. announced a non-brokered private placement of up to 16,000,000 common shares at $0.50 per share.
• The offering aims for gross proceeds of up to $8 million CAD/USD (currency not specified but implied local).
• Proceeds are designated for clinical development of TTI-0102 in cystinosis and Leigh syndrome, manufacturing scale-up, and working capital.
• Expected closing is by the end of May 2026, subject to TSX Venture Exchange approval.
• Shares issued will be subject to a four-month and one-day hold period.
• The offering price ($0.50) is below the recent trading range observed in April and early May 2026 (approx. $0.51-$0.56).

• Dilution Risk: The issuance of 16 million shares represents significant dilution to existing shareholders, reducing ownership percentage and earnings per share metrics on a fully diluted basis.
• Valuation Discount: Pricing the offering at $0.50 against a recent market close of ~$0.56 indicates management is willing to sell equity below current market levels to secure capital quickly. This often signals immediate downward pressure on the stock price as arbitrageurs and existing holders adjust valuations.
• Runway Extension: The $8 million provides necessary liquidity for Phase 3 cystinosis trials and Phase 2a Leigh syndrome studies, preventing near-term insolvency risk. However, it does not alter the fundamental binary nature of clinical success or failure.
• Transcript Discrepancy Note: The provided transcript context references "TETRA Technologies" (Oilfield Services/Bromine/Lithium) and is completely irrelevant to Thiogenesis Therapeutics. This data was excluded from analysis as it pertains to a different entity entirely, highlighting the need for rigorous source verification before investment decisions.
• Market Sentiment: The stock price had been trending downward since July 2025 ($0.84 high) prior to this announcement. The financing confirms the market's expectation of capital needs but at a discounted valuation, reinforcing negative sentiment regarding short-term shareholder value.

• Company: Thiogenesis Therapeutics Corp. focuses on developing novel therapies for rare genetic diseases, specifically mitochondrial disorders and lysosomal storage disorders.
• Flagship Candidate: TTI-0102 is a sulfur-based disulfide prodrug delivering sustained cysteamine exposure with reduced peak-related GI toxicity compared to existing therapies (Cystagon/Procysbi).
• Development Pipeline:
  • Nephropathic Cystinosis: Phase 3 pivotal trial planned under FDA 505(b)(2) pathway. Market opportunity >$300 million.
  • Leigh Syndrome: Phase 2a IND-cleared trial (MM-COAST outcome framework).
  • MELAS: Interim Phase 2 data presented at Mitocon 2026 showing fatigue improvement and favorable PK/PD profiles.
• Manufacturing: Scaling up a newly patented salt formulation of TTI-0102 to support clinical material needs.